Evaluating heart involvement in patients with Fabry disease
Official title: Prospective Monocentric Cohort Study to Evaluate Predictors for Heart Failure and Sudden Cardiac Death in Patients With Fabry Disease
Run by Wuerzburg University Hospital · NCT03362164 · Data updated 2026-11-12
This study looks at patients with Fabry disease to see what factors might lead to heart problems like arrhythmias and heart failure.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 650 (estimated) |
| Sponsor | Wuerzburg University Hospital Academic / other |
| Locations | 1 site (Würzburg, Bavaria) |
| Status | Recruiting |
| Started | January 2001 |
| Main results expected | March 2032 |
| Study ends | March 2032 |
| Registry record updated | July 7, 2022 |
| Trial ID | NCT03362164 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with genetically confirmed Fabry disease.
✕Probably not a fit
Patients who do not provide informed consent or withdraw consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with Fabry disease to evaluate predictors for the incidence of arrhythmias, sudden cardiac death, and terminal heart failure. It is a prospective cohort study that has been observing patients since 2001, leveraging long-term data to estimate cardiac risks associated with this rare lysosomal storage disorder. The study includes all patients receiving treatment at the Fabry Center Wuerzburg who provide informed consent.
Why it matters
Potential benefit: If successful, this study could improve understanding of cardiac risks in Fabry disease patients, potentially leading to better management and treatment strategies.
How similar studies have gone: While the study addresses a rare condition, similar observational studies have shown success in understanding cardiac implications in other lysosomal storage disorders.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fabry disease (genetically confirmed) * Signed informed consent * 18 years and older Exclusion Criteria: * No informed consent * Withdrawal of informed consent
Where it's running
-
Wuerzburg University Hospital
Würzburg, Bavaria, Germany Recruiting
Study contacts
- Principal investigator: Peter Nordbeck, MD, PhD — Wuerzburg University Hospital
- Study coordinator: Peter Nordbeck, MD, PhD
- Email: nordbeck_p@ukw.de
- Phone: 004993120139181
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry for Rare Diseases
This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.
-
Lucerastat in untreated adult men with Fabry disease shows how well it works and safety
This study tests lucerastat to see if it can reduce Gb3 buildup and be safe in untreated adult men with Fabry disease.
-
AI-assisted Rare-Disease Diagnosis
A multicenter randomized test to see if an AI diagnostic tool can help doctors make faster, more accurate rare-disease diagnoses for patients with unresolved symptoms.
-
Periodontal Health in Rare Kidney Conditions and Controls
This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.
-
Socio‑professional inclusion for young people (15–25) with childhood-onset rare genetic disabilities
This project will try to see what makes it hard for 15–25‑year‑olds with childhood-onset rare genetic conditions to access higher education, internships, or work.
-
Anderson-Fabry disease fitness improvement program
This study tests whether a 12-week physiotherapy-led exercise program can improve function, fitness, strength, and quality of life in adults with Fabry disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.